Aquestive Therapeutics (AQST) Revenue & Revenue Breakdown
Aquestive Therapeutics Revenue Highlights
Latest Revenue (Y)
$44.55M
Latest Revenue (Q)
$14.45M
Main Segment (Y)
Manufacture and Supply Revenue
Main Geography (Y)
UNITED STATES
Aquestive Therapeutics Revenue by Period
Aquestive Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $44.55M | -22.61% |
| 2024-12-31 | $57.56M | 13.80% |
| 2023-12-31 | $50.58M | 6.09% |
| 2022-12-31 | $47.68M | -6.20% |
| 2021-12-31 | $50.83M | 10.87% |
| 2020-12-31 | $45.85M | -12.85% |
| 2019-12-31 | $52.61M | -21.98% |
| 2018-12-31 | $67.43M | 0.77% |
| 2017-12-31 | $66.92M | 29.22% |
| 2016-12-31 | $51.78M | - |
Aquestive Therapeutics generated $44.55M in revenue during NA 2025, up -22.61% compared to the previous quarter, and up 97.16% compared to the same period a year ago.
Aquestive Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | $14.45M | 11.00% |
| 2025-12-31 | $13.02M | 1.62% |
| 2025-09-30 | $12.81M | 28.03% |
| 2025-06-30 | $10.00M | 14.71% |
| 2025-03-31 | $8.72M | -26.52% |
| 2024-12-31 | $11.87M | -12.37% |
| 2024-09-30 | $13.54M | -32.62% |
| 2024-06-30 | $20.10M | 66.76% |
| 2024-03-31 | $12.05M | -8.73% |
| 2023-12-31 | $13.21M | 1.57% |
| 2023-09-30 | $13.00M | -1.80% |
| 2023-06-30 | $13.24M | 18.92% |
| 2023-03-31 | $11.13M | 4.23% |
| 2022-12-31 | $10.68M | -6.81% |
| 2022-09-30 | $11.46M | -13.58% |
| 2022-06-30 | $13.27M | 8.11% |
| 2022-03-31 | $12.27M | 10.76% |
| 2021-12-31 | $11.08M | -16.63% |
| 2021-09-30 | $13.29M | -13.41% |
| 2021-06-30 | $15.35M | 37.97% |
| 2021-03-31 | $11.12M | 55.57% |
| 2020-12-31 | $7.15M | -13.45% |
| 2020-09-30 | $8.26M | -61.89% |
| 2020-06-30 | $21.68M | 147.29% |
| 2020-03-31 | $8.77M | -46.62% |
| 2019-12-31 | $16.42M | 32.22% |
| 2019-09-30 | $12.42M | 11.58% |
| 2019-06-30 | $11.13M | -11.98% |
| 2019-03-31 | $12.64M | -24.85% |
| 2018-12-31 | $16.82M | 26.81% |
| 2018-09-30 | $13.27M | -4.75% |
| 2018-06-30 | $13.93M | -40.51% |
| 2018-03-31 | $23.41M | 91.97% |
| 2017-12-31 | $12.20M | -55.08% |
| 2017-09-30 | $27.15M | 143.64% |
| 2017-06-30 | $11.14M | -32.21% |
| 2017-03-31 | $16.44M | - |
Aquestive Therapeutics generated $14.45M in revenue during Q1 2026, up 11.00% compared to the previous quarter, and up 121.73% compared to the same period a year ago.
Aquestive Therapeutics Revenue Breakdown
Aquestive Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Manufacture and Supply Revenue | $40.23M | $39.98M | $43.80M | $36.38M | $35.31M |
| Co-Development and Research Fees | $1.28M | $1.93M | $1.40M | $1.29M | $1.64M |
| License and Royalty Revenue | $3.52M | $15.35M | $5.38M | $2.35M | $5.38M |
| Proprietary Product Sales | - | - | - | $7.66M | $8.51M |
| Royalty | - | - | - | $-916.00K | $-1.10M |
Aquestive Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Manufacture and Supply Revenue (89.34%), License and Royalty Revenue (7.82%), and Co-Development and Research Fees (2.84%).
Quarterly Revenue by Product
| Product/Service | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Co-Development and Research Fees | $258.00K | $181.00K | $302.00K | $378.00K | $418.00K | $1.03M | $492.00K | $403.00K | $335.00K | $490.00K | $124.00K | $453.00K | $254.00K | $395.00K | $241.00K | $403.00K | $218.00K | $523.00K | $456.00K | - |
| License and Royalty Revenue | $5.39M | $852.00K | $1.04M | $839.00K | $790.00K | $12.05M | $2.16M | $1.13M | $1.87M | $1.10M | $1.48M | $919.00K | $917.00K | $376.00K | $552.00K | $506.00K | $380.00K | $328.00K | $2.36M | - |
| Manufacture and Supply Revenue | $8.79M | $11.98M | $11.47M | $9.58M | $7.19M | $18.79M | $10.67M | $10.52M | $11.00M | $11.41M | $11.64M | $9.76M | $8.92M | $8.41M | $9.87M | $9.17M | $7.69M | $10.45M | $10.66M | $6.51M |
| Manufactured Product, Other | - | - | - | $-797.00K | $319.00K | $217.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Proprietary Product Sales | - | - | - | - | - | - | - | - | - | - | - | - | $589.00K | $2.28M | $2.60M | $2.19M | $2.79M | $1.99M | $1.91M | - |
| Royalty | - | - | - | - | - | - | - | - | - | - | - | - | $-13.00K | $-25.00K | - | - | - | - | - | - |
Aquestive Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Manufacture and Supply Revenue (60.87%), License and Royalty Revenue (37.35%), and Co-Development and Research Fees (1.79%).
Aquestive Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Non-US | $14.94M | $17.63M | $13.48M | $7.76M | $7.97M |
| UNITED STATES | $29.60M | $39.93M | $37.10M | $39.92M | $42.86M |
Aquestive Therapeutics's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (66.46%), and Non-US (33.54%).
Quarterly Revenue by Country
| Country | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $1.20M | $3.63M | $2.68M | $5.11M | $3.52M | $12.99M | $3.01M | $1.63M | $1.47M | $3.11M | $5.93M | $2.97M | $2.18M | $2.38M | $2.01M | $1.19M | $1.71M | $2.76M | $2.24M | $1.69M |
| UNITED STATES | $13.24M | $9.39M | $10.12M | $4.89M | $5.20M | $18.98M | $10.53M | $10.43M | $11.73M | $9.89M | $7.31M | $8.16M | $8.51M | $9.08M | $11.26M | $11.08M | $9.37M | $10.53M | $13.11M | - |
| United States | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $5.46M |
Aquestive Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 26: UNITED STATES (91.69%), and Non-US (8.31%).
Aquestive Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SNDL | SNDL | $909.01M | $197.75M |
| EBS | Emergent BioSolutions | $742.90M | $231.10M |
| ESPR | Esperion Therapeutics | $403.13M | $80.10M |
| ARVN | Arvinas | $262.60M | $15.60M |
| SIGA | SIGA | $94.60M | $6.24M |
| AQST | Aquestive Therapeutics | $44.55M | $14.45M |
| DRIO | DarioHealth | $22.36M | $5.58M |
| AVXL | Anavex Life Sciences | - | - |
| MLTX | MoonLake Immunotherapeutics | - | - |
| OFIX | Orthofix Medical | - | $196.71M |
| ERAS | Erasca | - | - |